Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Molecular Partners AG American Depositary Shares stock

Learn how to easily invest in Molecular Partners AG American Depositary Shares stock.

Molecular Partners AG American Depositary Shares is a biotechnology business based in the US. Molecular Partners AG American Depositary Shares shares (MOLN) are listed on the NASDAQ and all prices are listed in US Dollars. Molecular Partners AG American Depositary Shares employs 152 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Molecular Partners AG American Depositary Shares

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MOLN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Molecular Partners AG American Depositary Shares stock price (NASDAQ: MOLN)

Use our graph to track the performance of MOLN stocks over time.

Molecular Partners AG American Depositary Shares shares at a glance

Information last updated 2021-07-28.
52-week range$14.54 - $28.70
50-day moving average $19.55
200-day moving average $19.55
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Molecular Partners AG American Depositary Shares shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Molecular Partners AG American Depositary Shares stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Molecular Partners AG American Depositary Shares financials

Revenue TTM $6.5 million
Gross profit TTM $-46,731,000
Return on assets TTM 0%
Return on equity TTM -88.62%
Profit margin 0%
Book value $3.25
Market capitalisation $579.6 million

TTM: trailing 12 months

Shorting Molecular Partners AG American Depositary Shares shares

There are currently 43,218 Molecular Partners AG American Depositary Shares shares held short by investors – that's known as Molecular Partners AG American Depositary Shares's "short interest". This figure is 109.6% up from 20,624 last month.

There are a few different ways that this level of interest in shorting Molecular Partners AG American Depositary Shares shares can be evaluated.

Molecular Partners AG American Depositary Shares's "short interest ratio" (SIR)

Molecular Partners AG American Depositary Shares's "short interest ratio" (SIR) is the quantity of Molecular Partners AG American Depositary Shares shares currently shorted divided by the average quantity of Molecular Partners AG American Depositary Shares shares traded daily (recently around 227463.15789474). Molecular Partners AG American Depositary Shares's SIR currently stands at 0.19. In other words for every 100,000 Molecular Partners AG American Depositary Shares shares traded daily on the market, roughly 190 shares are currently held short.

To gain some more context, you can compare Molecular Partners AG American Depositary Shares's short interest ratio against those of similar companies.

However Molecular Partners AG American Depositary Shares's short interest can also be evaluated against the total number of Molecular Partners AG American Depositary Shares shares, or, against the total number of tradable Molecular Partners AG American Depositary Shares shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Molecular Partners AG American Depositary Shares's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Molecular Partners AG American Depositary Shares shares in existence, roughly 0 shares are currently held short) or 0.0023% of the tradable shares (for every 100,000 tradable Molecular Partners AG American Depositary Shares shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Molecular Partners AG American Depositary Shares.

Find out more about how you can short Molecular Partners AG American Depositary Shares stock.

Molecular Partners AG American Depositary Shares share dividends

We're not expecting Molecular Partners AG American Depositary Shares to pay a dividend over the next 12 months.

Molecular Partners AG American Depositary Shares share price volatility

Over the last 12 months, Molecular Partners AG American Depositary Shares's shares have ranged in value from as little as $14.54 up to $28.7. A popular way to gauge a stock's volatility is its "beta".

MOLN.US volatility(beta: 0.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Molecular Partners AG American Depositary Shares's is 0.6644. This would suggest that Molecular Partners AG American Depositary Shares's shares are less volatile than average (for this exchange).

To put Molecular Partners AG American Depositary Shares's beta into context you can compare it against those of similar companies.

Molecular Partners AG American Depositary Shares overview

Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA; and collaboration with AGC Biologics to develop anti-COVID-19 DARPin program. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland. .

Frequently asked questions

How many people work for Molecular Partners AG American Depositary Shares?
Latest data suggests 152 work at Molecular Partners AG American Depositary Shares.
When does the fiscal year end for Molecular Partners AG American Depositary Shares?
Molecular Partners AG American Depositary Shares's fiscal year ends in December.
Where is Molecular Partners AG American Depositary Shares based?
Molecular Partners AG American Depositary Shares's address is: Wagistrasse 14, Schlieren, Switzerland, 8952

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site